Baseline Therapeutics
1 known investors
Baseline develops a GLP-1 receptor agonist weekly injectable therapeutic targeting alcohol use disorder (AUD) and other substance use disorders. The company is advancing its treatment toward Phase 3 trials for AUD in 2026, addressing addictive disorders in the pharmaceutical/therapeutics space.
BiotechDigital Health